These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24251571)

  • 1. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
    Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
    Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
    Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
    Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy.
    Cheng W; Zhou J; Tian X; Zhang X
    Curr Med Chem; 2016; 23(29):3343-3359. PubMed ID: 27160532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the HER-kinase axis in cancer.
    Gross ME; Shazer RL; Agus DB
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
    Cheng W; Hu Y; Sheng R
    Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER family inhibitors in pancreatic cancer: current status and future directions.
    Berz D; Miner T; McCormack E; Safran H
    Expert Opin Ther Targets; 2007 Mar; 11(3):337-47. PubMed ID: 17298292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
    Sabbah DA; Hajjo R; Sweidan K
    Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the EGF/HER Ligand-Receptor System in Cancer.
    Esparís-Ogando A; Montero JC; Arribas J; Ocaña A; Pandiella A
    Curr Pharm Des; 2016; 22(39):5887-5898. PubMed ID: 27426127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
    Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
    Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancer.
    Albanell J
    Adv Exp Med Biol; 2006; 587():329-40. PubMed ID: 17163175
    [No Abstract]   [Full Text] [Related]  

  • 12. EGFR/HER-targeted therapeutics in ovarian cancer.
    Wilken JA; Badri T; Cross S; Raji R; Santin AD; Schwartz P; Branscum AJ; Baron AT; Sakhitab AI; Maihle NJ
    Future Med Chem; 2012 Mar; 4(4):447-69. PubMed ID: 22416774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
    Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
    Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
    Mora Vidal R; Regufe da Mota S; Hayden A; Markham H; Douglas J; Packham G; Crabb SJ
    Urology; 2018 Feb; 112():225.e1-225.e7. PubMed ID: 29154981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
    Aertgeerts K; Skene R; Yano J; Sang BC; Zou H; Snell G; Jennings A; Iwamoto K; Habuka N; Hirokawa A; Ishikawa T; Tanaka T; Miki H; Ohta Y; Sogabe S
    J Biol Chem; 2011 May; 286(21):18756-65. PubMed ID: 21454582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.
    Hatake K; Tokudome N; Ito Y
    Breast Cancer; 2007; 14(2):132-49. PubMed ID: 17485898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.
    Ako E; Yamashita Y; Ohira M; Yamazaki M; Hori T; Kubo N; Sawada T; Hirakawa K
    Oncol Rep; 2007 Apr; 17(4):887-93. PubMed ID: 17342332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer.
    Bregni G; Sciallero S; Sobrero A
    JAMA Oncol; 2019 May; 5(5):605-606. PubMed ID: 30869746
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.